RedDress Multi-Center Study Results Demonstrate the Safety and Efficacy of ActiGraft® System to Treat Hard-to-Heal Wounds

RedDress recently published an article on Wounds International titled, An Observational Pilot Study to Collect Safety and Efficacy Data on Wound Care Using Whole Blood Clot Technology on Hard-to-Heal Wounds, that demonstrates the safety and efficacy for whole blood clot (WBC) technology in a wide variety of hard-to-heal wounds such as Diabetic Foot Ulcers, Vascular Ulcers, Pressure Injuries, and non-healing surgical site infections.

This multi-center observational pilot study explored the use of ActiGraft® WBC (whole blood clot) therapy on hard-to-heal wounds where the phases of wound healing have been interrupted or stalled. Data from the study showed the following:

  • Prior to the application of the WBC technology, several advanced wound care therapies were used in 55% of patients for more than 12 months without achieving wound closure.
  • An average of 65% reduction in wound size was achieved by week 4 and 94% by week 12.
  • In 4 of the cases described, not only did patients experience healing in hard-to-heal wounds, but scheduled amputations were avoided.

Case Study 4 – Wound Progression

These findings illustrate the safety and efficacy for WBC application in a variety of hard-to-to-heal wounds such as DFUs, vascular ulcers, pressure injuries, and non-healing surgical site infections. Based on wound size reduction results, it is suggested that the application of WBC technology changes the chronic nature of the hard-to-heal wound into an acute wound healing trajectory significantly faster than what is suggested in the literature.

Based on the findings in the observational pilot study, it is recommended that healthcare systems and insurance companies use WBC in hard-to-heal wounds to achieve complete healing and, thus, reduce the ongoing burden to the patient and associated costs.

To learn more, read the full publication HERE

To learn more about ActiGraft and how it can benefit your practice visit: